Cite
HARVARD Citation
Fang, W. et al. (2018). Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet oncology. 19 (10), pp. 1338-1350. [Online].